Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 10/20 | 0.55 |
| ▸ | DGAT1 | O75907 | 10/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.51 |
| ▸ | SOAT1 | P35610 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10326024 | 0.95 | NPBWR1 (0.62) | NPBWR1DGAT1KCNH2SOAT1 | |
| SCHEMBL14971553 | 0.88 | NPBWR1 (0.52) | NPBWR1DGAT1KCNH2SOAT1 | |
| SCHEMBL10326325 | 0.86 | NPBWR1 (0.55) | NPBWR1DGAT1KCNH2SOAT1 | |
| SCHEMBL4566490 | 0.85 | NPC1 (0.60) | NPBWR1DGAT1KCNH2SOAT1 | |
| SCHEMBL15245140 | 0.83 | DGAT1 (0.67) | NPBWR1DGAT1KCNH2SOAT1 | |
| SCHEMBL15231306 | 0.82 | DGAT1 (0.61) | NPBWR1DGAT1KCNH2SOAT1 | |
| SCHEMBL15626605 | 0.81 | NPC1 (0.50) | NPBWR1 | |
| SCHEMBL1687838 | 0.81 | NPC1 (0.58) | DGAT1KCNH2SOAT1 | |
| SCHEMBL15231864 | 0.81 | NPBWR1 (0.84) | NPBWR1DGAT1KCNH2SOAT1 | |
| SCHEMBL15245185 | 0.81 | DGAT1 (0.63) | NPBWR1DGAT1KCNH2SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140088124-A1 | IMIDAZOLE DERIVATIVES | INTERVET INC. | 2014-03-27 | — | — | US | disclosed |
| US-20140088124-A1 | IMIDAZOLE DERIVATIVES | INTERVET INC. | 2014-03-27 | — | — | US | disclosed |
| WO-2012164071-A1 | IMIDAZOLE DERIVATIVES | INTERVET INTERNATIONAL B.V. (NL) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012164071-A1 | IMIDAZOLE DERIVATIVES | INTERVET INTERNATIONAL B.V. (NL) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012064569-A1 | IMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012009217-A1 | SPIROCYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088124-A1 | IMIDAZOLE DERIVATIVES | DGAT1, DGAT2, SOAT1 | NPBWR1 1272/4885DGAT1 1/4885KCNH2 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.